Voice attractiveness: influence of stimulus duration and type.

Voice attractiveness is a relatively new area of research. Some aspects of the methodology used in this domain deserve particular attention. Especially, the duration of voice samples is often neglected as a factor and happens to be manipulated without the perceptual consequences of these manipulations being known. Moreover, the type of voice stimulus varies from a single vowel to complex sentences. The aim of this experiment was to investigate the extent to which stimulus duration (nonmanipulated vs. normalized) and type (vowel vs. word) influence perceived voice attractiveness. Twenty-seven male and female raters made attractiveness judgments of 30 male and female voice samples. Voice samples included a single vowel /a/, a three-vowel series /i a o/, and the French word "bonjour" (i.e., "hello"). These samples were presented in three conditions: nonmanipulated, shortened, and lengthened duration. Duration manipulation was performed using the pitch synchronous overlap and add (PSOLA) algorithm implemented in Praat. Results for the effect of stimulus type showed that word length samples were more attractive to the opposite sex than vowels. Results for the effect of duration showed that the nonmanipulated sound sample duration was not predictive of perceived attractiveness. Duration manipulation, on the other hand, altered perceived attractiveness for the lengthening condition. In particular, there was a linear decrease in attractiveness as a function of modification percentage (especially for the word, as compared with the vowels). Recommendations for voice sample normalization with the PSOLA algorithm are thus to prefer shortening over lengthening and, if not possible, to limit the extent of duration manipulation-for example, by normalizing to the mean sample duration.

Evaluating the morbidity and long-term efficacy of laparoscopic sacrocolpopexy with and without robotic assistance for pelvic organ prolapse.

OBJECTIVE: The aim of our study was to compare the morbidity and long-term efficacy after laparoscopic sacrocolpopexy with and without robotic assistance. METHODS: We conducted a retrospective chart review of all laparoscopic or robotic sacrocolpopexies for POP-Q stage 2-4 vaginal prolapse performed between September 2015 and October 2018 in 2 Gynecologic Surgery Departments of France. Patients were separated into two groups: a laparoscopic sacrocolpopexy group (LS) and a robotic-assisted sacrocolpopexy group (RAS). The primary outcome measure was reoperation procedures for recurrent pelvic organ prolapse (POP). RESULTS: Two hundred and fourteen patients were included, 160 patients (75%) in the LS group and 54 patients (25%) in the RAS group. After a mean follow-up of 32.8 months, reoperation rate for recurrent POP and the recurrent POP rate were greater in the RAS group (9.2% versus 1.2%, p = 0.01 and 25.9% versus 7.5%, p = 0.0003, respectively). No significant difference was found in terms of immediate intraoperative (3.1% versus 1.8%, p = 1) and postoperative complications (1.9% versus 1.8%, p = 1). On comparing the 2 groups by bivariate analysis, RAS significantly increased the odds of reoperation for POP recurrence (OR = 7.8 CI 95% [1.5-41.6], p = 0.02) and the odds of global reoperation (OR = 3.8 CI 95% [1.4-10.4], p = 0.0095). Similarly, multivariate logistic analysis showed that RAS increased the risks of global reoperation (OR = 3.8 CI 95% [1.3-10.6], p = 0.01) after controlling high-grade prolapse. CONCLUSION: Robotic sacrocolpopexy does not appear to give long-term clinical benefits. Recurrent POP and reoperation procedures seem to be more frequent in case of robotic-assisted surgery.

[Can new molecular profiles in epithelial ovarian cancer modify therapeutics?] / Les nouveaux profils moléculaires dans le cancer de l'ovaire peuvent-ils modifier les stratégies thérapeutiques ?

Epithelial ovarian cancer (EOC) affects 4500 women a year in France, with a survival of 30% at 5 years. Treatment is based on extensive surgery and chemotherapy. Around 15% of EOCs are due to genetic mutation predisposition essentially with mutated BRCA1 and BRCA2 genes. Four histological subtypes are described (serous, endometrioid, and mucinous cells to clear), corresponding to different carcinogenesis and distinct molecular mutations. High-grade serous EOCs have a mutation of the BRCA genes in 20-30% of cases. This mutation causes a deficit of repair by homologous recombination of DNA in case of double strand break, allowing greater sensitivity to platinum salts and the use of PARP inhibitors, a protein involved in the repair of single-strand breaks of DNA. PARP inhibitors have shown efficacy in patients mutated BRCA but this effectiveness remains to be demonstrated in patients without congenital mutation, but with acquired BRCAness profile EOC. The BRCAness profile is defined by a tumor having a defect in DNA repair counterpart (not limited to BRCA mutation). Molecular definition of BRCAness is still not consensual but is necessary for the use of PARP inhibitors. Gene expression analyses have identified four subgroups of high-grade serous CEO: mesenchymal, proliferative, differentiated and immunoreactive. These four subtypes, not mutually exclusive, although correlated with prognosis, are not yet used in clinical routine.